Cerus to Present at the Stifel Nicolaus Weisel Healthcare Conference on September 5, 2012

Cerus to Present at the Stifel Nicolaus Weisel Healthcare Conference on September 5, 2012

Cerus CorporationLainie Corten, 925-288-6319Senior Director, Global Marketing & Investor Relations

Cerus Corporation (NASDAQ:CERS) announced today that Dr. Laurence Corash, chief medical officer, is scheduled to present a corporate update at the Stifel Nicolaus Weisel Healthcare Conference in Boston at 9:45 AM ET on Wednesday, September 5, 2012.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at . A replay will be available for approximately two weeks following the completion of the event.

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Blood System for red blood cells is in clinical development. See  for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.